1. Scrip
  2. >>Business
  3. >>Deals

BMS Spends $100m On Orum’s Antibody-Guided Protein Degrader

 
• By Elizabeth Cairns

ORM-6151 combines two hot approaches in cancer R&D, but clinical trials have not yet started.  

Closeup Of Handshake
• Source: Shutterstock

Today’s deal between Bristol Myers Squibb Company and Orum Therapeutics is by no means the biggest over antibody-drug conjugates to have been signed this year, but is notable for the interesting combination of technologies it employs.

Key Takeaways
  • BMS pays $100m upfront for ORM-6151, plus $80m in potential milestones
  • ORM-6151 is a GSPT1 degrader, like two discontinued BMS products
  • Monte Rosa Therapeutics has a more advanced GSPT1

BMS has paid $100m upfront to acquire Orum’s ORM-6151, an anti-CD33 antibody conjugated to a degrader of GSPT1, a translation termination factor being explored as a therapeutic target for the treatment of acute myeloid leukemia (AML)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Business

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.